All In Biotech

Drug Trial Radar · NCT03306394

A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).

An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer (PRECONNECT)

Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

907

Actual

Start

Oct 18, 2016

Primary completion

Nov 30, 2020

Study completion Nov 30, 2020

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ADIR, a Servier Group company
First posted
Oct 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC). Eligible patients may receive an early access to trifluridine / tipiracil through this clinical study until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • Trifluridine/Tipiracil hydrochloride (S95005)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events [safety and tolerability]Time frame: Through 28 days following last administration of study medication
  2. Abnormalities in laboratory assessmentTime frame: Through study completion, an average of 12 weeks
  3. Abnormalities in performance status (ECOG)Time frame: Through study completion, an average of 12 weeks
  4. Abnormalities in vital signsTime frame: Through study completion, an average of 12 weeks

Locations

99 sites in 16 countries. Site status is shown where the registry gives one.

  • Chris O'Brien Lifehouse Oncology

    Camperdown, Australia

  • St Vincent's Hospital The Kinghorn Cancer Centre

    Darlinghurst, Australia

  • St Vincent's Hospital (Melbourne) Cancer Centre

    Fitzroy, Australia

  • The Canberra Hospital Cancer,Ambulatory & Community Health Service (CACHS) Bldg 19

    Garran, Australia

  • Royal Brisbane & Women's Hospital Clinical Research Unit

    Herston, Australia

  • Cabrini Hospital Cabrini Haematology and Oncology Centre

    Malvern, Australia

  • Perth Oncology - Mount Hospital

    Perth, Australia

  • The Queen Elizabeth Hospital Haematology and Oncology Unit

    Woodville, Australia

  • Hôpital Universitaire Erasme Gastro-Entérologie

    Brussels, Belgium

  • Cliniques Universitaires St. Luc Oncologie médicale

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen Oncologie

    Edegem, Belgium

  • U.Z. Gent Digestieve Oncologie

    Ghent, Belgium

  • UZ Leuven Campus Gasthuisberg Digestieve Oncologie

    Leuven, Belgium

  • Hospital Mãe de Deus Centro Intergrado de Pesquisa

    Porto Alegre, Brazil

  • Clinicas Oncológicas Integradas (COI)

    Rio de Janeiro, Brazil

  • AMO Assistencia Multidisciplinar em Oncologia GEM Assistencia Medica Especializada

    Salvador, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP Núcleo de Pesquisa

    São Paulo, Brazil

  • Hospital A C Camargo Unidade de Pesquisa Clínica

    São Paulo, Brazil

  • Instituto Brasileiro de Controle do Câncer Unidadde de Pesquisa Clínica

    São Paulo, Brazil

  • Complex oncology center - Plovdiv

    Plovdiv, Bulgaria

  • Military Medical Academy - MHAT Oncology clinic

    Sofia, Bulgaria

  • Specialized hospital for active treatment in oncology

    Sofia, Bulgaria

  • SHAT of oncology diseases

    Varna, Bulgaria

  • Klinicki bolnicki centar Rijeka Klinika za radioterapiju i onkologiju

    Rijeka, Croatia

  • Klinicki bolnicki centar Zagreb Klinika za onkologiju

    Zagreb, Croatia

  • Hopital Privé Les Bonnettes Pharmacie centrale

    Arras, France

  • Institut Sainte Catherine Institut Sainte Catherine

    Avignon, France

  • Centre de lutte contre le cancer Francois Baclesse UCP Digestif

    Caen, France

  • Hôpital Trousseau Hépato-gastroentérologie et cancérologie digestive

    Chambray-lès-Tours, France

  • CHU Hôpital du Bocage/ François Mitterrand Hépato-gastroentérologie

    Dijon, France

  • CHU de Grenoble Oncologie médicale Hépato-gastroentérologie - 7D

    Grenoble, France

  • CHD - Les Oudairies service d'hepato-gastroenterologie

    La Roche-sur-Yon, France

  • Franco-British Institue Department of Medical Oncology

    Levallois-Perret, France

  • Hopital Privé Jean Mermoz Service de Gastro entérologie et d'Oncologie médicale

    Lyon, France

  • CRLCC Léon Bérard Service d'Oncologie

    Lyon, France

  • CHU de la Timone Hépato-Gastro-Entérologie

    Marseille, France

  • Hôpital Nord Franche-Comté - Site du Mittan Service d'oncologie médicale

    Montbéliard, France

  • CRLCC Val d'Aurelle Oncologie Médicale

    Montpellier, France

  • Centre Antoine Lacassagne Dpt d'Oncologie Médicale

    Nice, France

  • Hôpital Saint-Antoine Service d'Oncologie Médicale

    Paris, France

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.